Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance With Consistent Positive Findings Across Key ...

Robert Blum and Fady Malik, M.D., Ph.D, have been with Cytokinetics since its inception nearly three decades ago. | ...

By Sneha S K May 5 (Reuters) - Cytokinetics said on Tuesday its experimental heart disease drug significantly improved symptoms of a genetic heart condition in a late-stage trial, sending its shares ...

Learn which common medications you need to avoid when you have oHCM, including some for blood pressure and erectile ...

Topline data from the ACACIA-HCM study reveal that the cardiac myosin inhibitor aficamten met all primary and key secondary endpoints, offering a potential new treatment pathway for patients with ...

Cytokinetics' cardiac myosin inhibitor Myqorzo has succeeded where first-to-market Camzyos from Bristol Myers Squibb failed, ...

Treatment with aficamten significantly improved exercise capacity compared with placebo. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for aficamten for ...

Topline results announced today show gains in KCCQ and peak oxygen consumption—the full dataset is coming soon.

Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...

Please provide your email address to receive an email when new articles are posted on . Hypertrophic cardiomyopathy is the most common monogenic CV disorder, yet perhaps the most frequently ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...

Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern TimeSOUTH SAN FRANCISCO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- ...